{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-124279","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.474867+00:00","generated_at":"2026-05-29T12:15:59.389341+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025","bullets":["APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.","APG777 Phase 1 12-month data: half-life 77 days, near complete pSTAT6 inhibition, supports potential annual dosing in AD.","APG777 Phase 2 Part A 16-week topline data accelerated to mid-2025 due to strong enrollment.","Preclinical PoC for APG777+APG990 combo: Phase 1b vs DUPIXENT in AD planned for 2025, data 2H 2026.","APG333 (anti-TSLP) Phase 1 start by end 2024; combo with APG777 in asthma/COPD under planning."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-124279","json":"https://secwatch.observer/filing/0001104659-24-124279.json","markdown":"https://secwatch.observer/filing/0001104659-24-124279.md","text":"https://secwatch.observer/filing/0001104659-24-124279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/0001104659-24-124279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/tm2429855d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:15:59.389341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}